Evaluation of brivaracetam: a new drug to treat epilepsy

References

• Kwan P , Schachter SC , Brodie MJ. Drug-resistant epilepsy. New England J Med. 2011;365(10):919–926.
   PubMed Web of Science ®Google Scholar
• Perucca E , French J , Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 2007;6(9):793–804.
   PubMed Web of Science ®Google Scholar
• Abou-Khalil B. Levetiracetam in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2008;4(3):507–523.
   PubMedGoogle Scholar
• Pack AM . Brivaracetam, a novel antiepileptic drug: is it effective and safe? Results from one Phase III randomized trial. Epilepsy Curr. 2014;14(4):196–198.
   PubMed Web of Science ®Google Scholar
• Schmidt D , Schachter SC . Drug treatment of epilepsy in adults. Bmj. 2014;28:348–354.
   Google Scholar
• Ventola CL . Epilepsy management: newer agents, unmet needs, and future treatment strategies. P T. 2014;39(11):776–784, 792.
   PubMedGoogle Scholar
• Leach JP , Abassi H . Modern management of epilepsy. Clin Med. 2013;13(1):84–86.
   PubMed Web of Science ®Google Scholar
• Kaur H , Kumar B , Medhi B . Antiepileptic drugs in development pipeline: a recent update. eNeurologicalSci. 2016;4:42–51.
   PubMedGoogle Scholar
• Pavlov I , Schorge S . From treatment to cure: stopping seizures, preventing seizures, and reducing brain propensity to seize. Int Rev Neurobiol. 2014;114:279–299.
   PubMed Web of Science ®Google Scholar
• Coppola G , Iapadre G , Operto FF , et al. New developments in the management of partial-onset epilepsy: role of brivaracetam. Drug Des Devel Ther. 2017;11:643–657.
   PubMed Web of Science ®Google Scholar
• Klitgaard H , Matagne A , Nicolas JM , et al. Brivaracetam: rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment. Epilepsia. 2016;57(4):538–548.
   PubMed Web of Science ®Google Scholar
• Brandt C , May TW , Bien CG . Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base. Ther Adv Neurol Disord. 2016;9(6):474–482.
   PubMed Web of Science ®Google Scholar
• Qiu S , Tehrani KA , Sergeyev S , et al. Stereochemistry of the brivaracetam diastereoisomers. Chirality. 2016;28(3):215–225.
   PubMed Web of Science ®Google Scholar
• Malawska B , Brivaracetam: KK . A new drug in development for epilepsy and neuropathic pain. Expert Opin Investig Drugs. 2008;17(3):361–369.
   PubMed Web of Science ®Google Scholar
• Gillard M , Fuks B , Leclercq K , et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1–3):36–44.
   PubMed Web of Science ®Google Scholar
• Correa-Basurto J , Cuevas-Hernández RI , Phillips-Farfán BV , et al. Identification of the antiepileptic racetam binding site in the synaptic vesicle protein 2A by molecular dynamics and docking simulations. Front Cell Neurosci. 2015;9:125.
   PubMed Web of Science ®Google Scholar
• Ferlazzo E , Russo E , Mumoli L , et al. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat. 2015;11:2967–2973.
   PubMed Web of Science ®Google Scholar
• Mumoli L , Palleria C , Gasparini S , et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures. Drug Des Devel Ther. 2015;9:5719–5725.
   PubMed Web of Science ®Google Scholar
• Brivaracetam (Briviact) for epilepsy. Med Lett Drugs Ther. 2016;58(1499):95–96.
   PubMed Web of Science ®Google Scholar
• Nicolas JM , Hannestad J , Holden D , et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–209.
   PubMed Web of Science ®Google Scholar
• Yates SL , Fakhoury T , Liang W , et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52(Pt A):165–168.
   PubMed Web of Science ®Google Scholar
• Briviact, Summary of product characteristics . London (UK): European Medicines Agency; 2016 cited 2017 Feb 16 . Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003898/human_med_001945.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Drug Approval Package: Briviact (brivaracetam) . Silver Spring, Maryland USA: US Food and Drug Administration; 2016 cited 2017 Feb 17 . Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/205836-205837-205838-Briviact-TOC.cfm
   Google Scholar
• Otoul C , Watanabe S , McCabe S , et al. Relative bioavailability and bioequivalence of brivaracetam 10 mg/mL oral solution and 50-mg film-coated tablet. Clin Pharmacol Drug Dev. 2016. Published online 8 Jun 2016. DOI:10.1002/cpdd.275.
   PubMed Web of Science ®Google Scholar
• Stockis A , Hartstra J , Mollet M , et al. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus. Epilepsia. 2016;57(8):1288–1293.
   PubMed Web of Science ®Google Scholar
• Schoemaker R , Wade JR , Stockis A . Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol. 2016;56(12):1591–1602.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML , Sokalski A , Boulanger P , et al. Brivaracetam disposition in renal impairment. J Clin Pharmacol. 2012;52(12):1927–1933.
   PubMed Web of Science ®Google Scholar
• Klein P , Tyrlikova I , Brazdil M , et al. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother. 2016;17(2):283–295.
   PubMed Web of Science ®Google Scholar
• Rolan P , Sargentini-Maier ML , Pigeolet E , et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol. 2008;66(1):71–75.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML , Espie P , Coquette A , et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos. 2008;36:36–45.
   PubMed Web of Science ®Google Scholar
• Sargentini-Maier ML , Rolan P , Connell J , et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol. 2007;63:680–688.
   PubMed Web of Science ®Google Scholar
• Von Rosenstiel P . Brivaracetam (UCB 34714). Neurotherapeutics. 2007;4(1):84–87.
   PubMed Web of Science ®Google Scholar
• Stockis A , Watanabe S , Scheen AJ , et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos. 2016;44(6):792–799.
   PubMed Web of Science ®Google Scholar
• Strzelczyk A , Klein KM , Willems LM , et al. Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2016;9(5):637–645.
   PubMed Web of Science ®Google Scholar
• Stockis A , Watanabe S , Rouits E , et al. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. Drug Metab Pharmacokinet. 2014;29:394–399.
   PubMed Web of Science ®Google Scholar
• Bialer M , Johannessen SI , Levy RH , et al. Progress report on new antiepileptic drugs: a summary of the thirteenth Eilat conference on new antiepileptic drugs and devices (EILAT XIII). Epilepsia. 2017;58(2):181–221.
   PubMed Web of Science ®Google Scholar
• Nicolas JM , Chanteux H , Rosa M , et al. Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjects. Drug Metab Dispos. 2012;40(8):1466–1472.
   PubMed Web of Science ®Google Scholar
• Bialer M , Johannessen SI , Levy RH , et al. Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 2015;11:85–141.
   Web of Science ®Google Scholar
• Stockis A , Sargentini-Maier ML , Horsmans Y . Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol. 2013;53(6):633–641.
   PubMed Web of Science ®Google Scholar
• Meador KJ , Gevins A , Leese PT , et al. Neurocognitive effects of brivaracetam, levetiracetam, and lorazepam. Epilepsia. 2011;52(2):264–272.
   PubMed Web of Science ®Google Scholar
• Kasteleijn-Nolst Trenité DG , Genton P , et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69(10):1027–1034.
   PubMed Web of Science ®Google Scholar
• French JA , Costantini C , Brodsky A , et al.; N01193 Study Group . Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology. 2010;75(6):519–525.
   PubMed Web of Science ®Google Scholar
• Van Paesschen W , Hirsch E , Johnson M , et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia. 2013;54(1):89–97.
   PubMed Web of Science ®Google Scholar
• Biton V , Berkovic SF , Abou-Khalil B , et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55(1):57–66.
   PubMed Web of Science ®Google Scholar
• Ryvlin P , Werhahn KJ , Blaszczyk B , et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014;55(1):47–56.
   PubMed Web of Science ®Google Scholar
• Klein P , Schiemann J , Sperling MR , et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015;56(12):1890–1898.
   PubMed Web of Science ®Google Scholar
• Kwan P , Trinka E , Van Paesschen W , et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55(1):38–46.
   PubMed Web of Science ®Google Scholar
• Ben-Menachem E , Mameniškienė R , Quarato PP , et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016;87(3):314–323.
   PubMed Web of Science ®Google Scholar
• Moseley BD , Sperling MR , Asadi-Pooya AA , et al. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: pooled results from three Phase III studies. Epilepsy Res. 2016;127:179–185.
   PubMed Web of Science ®Google Scholar
• Kälviäinen R , Genton P , Andermann E , et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia. 2016;57(2):210–221.
   PubMed Web of Science ®Google Scholar
• UCB Pharma . A double-blind, randomized conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to 75 years old) with partial onset seizures. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 cited 2017 Feb 10 . Available from: https://clinicaltrials.gov/ct2/show/NCT00699283. NLM Identifier: NCT00699283.
   Google Scholar
• UCB Pharma . A double-blind, randomized conversion to monotherapy study to evaluate the efficacy and safety of brivaracetam in subjects (≥ 16 to 75 years old) with partial onset seizures. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 cited 2017 Feb 10 . Available from: https://clinicaltrials.gov/ct2/show/NCT00698581. NLM Identifier: NCT00698581.
   Google Scholar
• UCB Pharma S.P.R.L . Study to look at how effective Briviact is as add-on treatment for patients with epilepsy with partial onset seizures (BASE). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2000 cited 2017 Feb 10 . Available from: https://clinicaltrials.gov/ct2/show/NCT02687711. NLM Identifier: NCT02687711.
   Google Scholar
• Perucca P , Gilliam FG . Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11(9):792–802.
   PubMed Web of Science ®Google Scholar
• Gao L , Li S . Emerging drugs for partial-onset epilepsy: a review of brivaracetam. Ther Clin Risk Manag. 2016;12:719–734.
   PubMed Web of Science ®Google Scholar
• Ma J , Huang S , You C . Adjunctive brivaracetam for patients with refractory partial seizures: a meta-analysis of randomized placebo-controlled trials. Epilepsy Res. 2015;114:59–65.
   PubMed Web of Science ®Google Scholar
• Tian X , Yuan M , Zhou Q , et al. The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies. Expert Opin Pharmacother. 2015;16:1755–1767.
   PubMed Web of Science ®Google Scholar
• Klein P , Biton V , Dilley D , et al. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy. Epilepsia. 2016;57(7):1130–1138.
   PubMed Web of Science ®Google Scholar
• Rosillon D , Astruc B , Hulhoven R , et al. Effect of brivaracetam on cardiac repolarisation – a thorough QT study. Curr Med Res Opin. 2008;24(8):2327–2337.
   PubMed Web of Science ®Google Scholar
• Calabrò RS , Italiano D , Militi D , et al. Levetiracetam-associated loss of libido and anhedonia. Epilepsy Behav. 2012;24(2):283–284.
   PubMed Web of Science ®Google Scholar
• Pollard JR , French J . Antiepileptic drugs in development. Lancet Neurol. 2006;5:1064–1067.
   PubMed Web of Science ®Google Scholar
• Lattanzi S , Cagnetti C , Foschi N , et al. Brivaracetam add-on for refractory focal epilepsy: a systematic review and meta-analysis. Neurology. 2016;86(14):1344–1352.
   PubMed Web of Science ®Google Scholar